These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 14559988)

  • 1. Kit expression in small cell carcinomas of the lung: effects of chemotherapy.
    Rossi G; Cavazza A; Marchioni A; Migaldi M; Bavieri M; Facciolongo N; Petruzzelli S; Longo L; Tamberi S; Crinò L
    Mod Pathol; 2003 Oct; 16(10):1041-7. PubMed ID: 14559988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
    Krug LM; Crapanzano JP; Azzoli CG; Miller VA; Rizvi N; Gomez J; Kris MG; Pizzo B; Tyson L; Dunne M; Heelan RT
    Cancer; 2005 May; 103(10):2128-31. PubMed ID: 15812822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of c-kit expression in small cell lung cancer: prevalence and prognostic implications.
    Camps C; Sirera R; Bremnes RM; Garde J; Safont MJ; Blasco A; Berrocal A; Sánchez JJ; Calabuig C; Martorell M
    Lung Cancer; 2006 Jun; 52(3):343-7. PubMed ID: 16574270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of imatinib in patients with small cell lung cancer.
    Johnson BE; Fischer T; Fischer B; Dunlop D; Rischin D; Silberman S; Kowalski MO; Sayles D; Dimitrijevic S; Fletcher C; Hornick J; Salgia R; Le Chevalier T
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5880-7. PubMed ID: 14676110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced expression of metallothionein in human non-small-cell lung carcinomas following chemotherapy.
    Matsumoto Y; Oka M; Sakamoto A; Narasaki F; Fukuda M; Takatani H; Terashi K; Ikeda K; Tsurutani J; Nagashima S; Soda H; Kohno S
    Anticancer Res; 1997; 17(5B):3777-80. PubMed ID: 9427779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications.
    Micke P; Basrai M; Faldum A; Bittinger F; Rönnstrand L; Blaukat A; Beeh KM; Oesch F; Fischer B; Buhl R; Hengstler JG
    Clin Cancer Res; 2003 Jan; 9(1):188-94. PubMed ID: 12538468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.
    Reck M; von Pawel J; Macha HN; Kaukel E; Deppermann KM; Bonnet R; Ulm K; Hessler S; Gatzemeier U
    Lung Cancer; 2006 Jul; 53(1):67-75. PubMed ID: 16713013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis.
    Naeem M; Dahiya M; Clark JI; Creech SD; Alkan S
    Hum Pathol; 2002 Dec; 33(12):1182-7. PubMed ID: 12514786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
    Wolff NC; Randle DE; Egorin MJ; Minna JD; Ilaria RL
    Clin Cancer Res; 2004 May; 10(10):3528-34. PubMed ID: 15161712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chemotherapy in extended small-cell lung cancer. Retrospective analysis of two different series of patients treated with carboplatin and etoposide or ciclophosphamide-epidoxorubicin and etoposide].
    Tassinari D; Genestreti G; Pasquini E; Fantini M; Poggi B; Tamburini E; Papi M; Ioli G; Oliverio G; Fochessati F; Arcangeli V; Agostini V; Mianulli AM; Imola M; Fattori PP; Ravaioli A
    Recenti Prog Med; 2005 May; 96(5):234-9. PubMed ID: 15977652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of small cell lung cancer in elderly.
    Satoh H; Ishikawa H; Funayama Y; Yamashita YT; Kamma H; Ohtsuka M; Sekizawa K
    Anticancer Res; 1999; 19(5C):4507-10. PubMed ID: 10650801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl-2 expression as a predictor of chemosensitivities and survival in small cell lung cancer.
    Takayama K; Ogata K; Nakanishi Y; Yatsunami J; Kawasaki M; Hara N
    Cancer J Sci Am; 1996; 2(4):212-6. PubMed ID: 9166534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
    Rudin CM; Kozloff M; Hoffman PC; Edelman MJ; Karnauskas R; Tomek R; Szeto L; Vokes EE
    J Clin Oncol; 2004 Mar; 22(6):1110-7. PubMed ID: 15020613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD117+ small cell lung cancer lacks the asp 816-->val point mutation in exon 17.
    Mojica WD; Saxena R; Starostik P; Cheney RT
    Histopathology; 2005 Nov; 47(5):517-22. PubMed ID: 16242000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy.
    Yamazaki S; Sekine I; Matsuno Y; Takei H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T; Kodama T; Asamura H; Tsuchiya R; Saijo N
    Lung Cancer; 2005 Aug; 49(2):217-23. PubMed ID: 16022916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.
    Sonett JR; Suntharalingam M; Edelman MJ; Patel AB; Gamliel Z; Doyle A; Hausner P; Krasna M
    Ann Thorac Surg; 2004 Oct; 78(4):1200-5; discussion 1206. PubMed ID: 15464470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathological significance of expression of c-kit protein in neuroendocrine lung carcinoma].
    Zhao P; Hou N; Shao Y; Li XH
    Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(22):1526-9. PubMed ID: 16179109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of KIT expression in small cell lung cancer.
    López-Martin A; Ballestín C; Garcia-Carbonero R; Castaño A; Lopez-Ríos F; López-Encuentra A; Sánchez-Cespedes M; Castellano D; Bartolomé A; Cortés-Funes H; Paz-Ares L
    Lung Cancer; 2007 Jun; 56(3):405-13. PubMed ID: 17420067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713.
    Edelman MJ; Chansky K; Gaspar LE; Leigh B; Weiss GR; Taylor SA; Crowley J; Livingston R; Gandara DR
    J Clin Oncol; 2004 Jan; 22(1):127-32. PubMed ID: 14701775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.